Serial No. 09/787,327
Docket No. PU3514USw
Reply to Office Action of June 18, 2003

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1, 2, 3, 10, 11, 12, 13, 14, 16 - 21, 22, 23 canceled.

Claim 4 (currently amended) A pharmaceutical formulation comprising a combination according to claim 5 in association with one or more pharmaceutically acceptable carriers therefore.

Claim 5 (currently amended) A pharmaceutical formulation for use in the treatment of HBV comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected from (9-[(R) 2 (phosphonomethoxy)ethyl]adonine or a pharmaceutically acceptable derivative thereof; and bis(pivaloyloxymethyl)(9-[R)-2-(phosphonomethoxy)ethyl]adenine or a pharmaceutically acceptable derivative thereof wherein (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-pyrimidin-2-one and the second therapeutic agent are present in the range 40:1 to 1:1 by weight.

Claim 6 (currently amended) A formulation according to claim 4 claim 5 in unit dosage form.

Claim 7 (currently amended) A formulation according to elaim 4 claim 5 suitable for oral administration.

Claim 8 (previously presented) A formulation according to claim 5 comprising between 25 to 150 mg of lamivudine and 5 to 60 mg adefovir dipivoxil.

Claim 9 (currently amended) A formulation according to elaim 8 claim 5 comprising 100 mg of lamivudine and 10 mg adefovir dipivoxil.

Serial No. 09/787,327 Docket No. PU3514USw Reply to Office Action of June 18, 2003

Claim 15 (currently amended)

A method as claimed in claim 10 for the treatment of a mammal with an HBV infection resistant to nucleoside and/or nucleoside inhibitors of the replication of the hepatitis B virus comprising administration of a therapeutically effective amount of a combination comprising (2R,cis)-4-amino-1-(2-hydroxymethyl-1-,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof and a second therapeutic agent selected bis(pivaloyloxymethyl)(9-f(R)-2-(phosphonomethoxy)ethyl]adenine.

Claim 24 (new)

The method according to claim 15, wherein the ratio of (2R,cis)-4-amino-1-(2-hydroxymethyl-1-,3-oxathiolan-5-yl)-pyrimidin-2-one or a pharmaceutically acceptable derivative thereof to bis(pivaloyloxymethyl)(9-[(R)-2-(phosphonomethoxy)ethyl]adenine is 40:1 to 1:1.